Lesaffre confirms acquisition of biotech firm Gnosis
Gnosis was founded in 1989 and has established a name for itself for both ingredients and a range of products that are used in the cosmetics, pharma, nutraceutical and veterinary fields.
Lesaffre first acquired a majority shareholding in the Gnosis business three years ago, but has now built on that with the full acquisition of the company.
Acquisition expands Lesaffre capabilities
The acquisition means that Lesaffre now has skills and expertise in microbial fermentation and in the recovery of and purification of molecultes derived from yeasts and bacteria.
The company also expands its manufacturing and research facilities by adding Gnosis’s manufacturing sites in San Antonio, Switzerland and Pisticci, Italy, as well as commercial offices in the US and China and its R&D facility in Desio, near Milan
Lesaffre has developed its business on the back of nutritional and fortified yeasts, yeast fractions, probiotic yeasts and bacteria, for a wide range of applications that include wellbeing and personal care, as well as digestive health and immunity enhancement.
Changes to the Gnosis business
Te acquisition will mean that the Gnosis and Lesaffre Human Care teams will now act as one single unit, offering a unified range of products and services, with the aim of continuing the fast growth rate that both business have enjoyed in recent years.
"For the past three years, we have developed the cooperation between Lesaffre and Gnosis teams to become today a unique provider of products and services that are increasingly innovative and closely address our customer’s needs in the Nutrition and Health sectors,” Antoine Baule, Lesaffre's Chief Executive Officer.
“I would like to thank Renzo Berna, former CEO of Gnosis, for his relentless dedication to building a successful company, and my respect for the great accomplishment of his purpose.”
